SCHEMBL3858097

SCHEMBL3858097

CONC(Cc1c(C)n(Cc2ccc(OC(F)(F)F)cc2)c2ccccc12)C(=O)O

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ADAM17 P78536 4/20 0.56
PLA2G2A P14555 7/20 0.50
PPARG P37231 1/20 0.49
PLA2G1B P04054 1/20 0.48
LMNA P02545 2/20 0.46
CYP1A2 P05177 2/20 0.46
CYP3A4 P08684 2/20 0.46
CYP2C9 P11712 2/20 0.46
TSHR P16473 2/20 0.46
CYP2C19 P33261 2/20 0.46
PMP22 Q01453 2/20 0.46
KDM4E B2RXH2 1/20 0.46
BLM P54132 1/20 0.46
NPSR1 Q6W5P4 1/20 0.46
PTGDR2 Q9Y5Y4 1/20 0.46
GFER P55789 1/20 0.45
MEN1 O00255 1/20 0.44
RGS12 O14924 1/20 0.44
ALDH1A1 P00352 1/20 0.44
MAPT P10636 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3858100 1.00 ADAM17 (0.56) ADAM17PLA2G2APPARGPLA2G1BLMNA
SCHEMBL3855489 0.92 ADAM17 (0.54) ADAM17PLA2G2APPARGPLA2G1BLMNA
SCHEMBL3855493 0.92 ADAM17 (0.54) ADAM17PLA2G2APPARGPLA2G1BLMNA
SCHEMBL3849889 0.90 PPARG (0.53) ADAM17PLA2G2APPARGPLA2G1BCYP1A2
SCHEMBL3849887 0.90 PPARG (0.53) ADAM17PLA2G2APPARGPLA2G1BCYP1A2
SCHEMBL3854426 0.89 PLA2G2A (0.49) ADAM17PLA2G2APPARGPLA2G1BPTGDR2
SCHEMBL3854423 0.89 PLA2G2A (0.49) ADAM17PLA2G2APPARGPLA2G1BPTGDR2
SCHEMBL3855369 0.87 PLA2G2A (0.51) ADAM17PLA2G2APLA2G1BKDM4EPTGDR2
SCHEMBL3855368 0.87 PLA2G2A (0.51) ADAM17PLA2G2APLA2G1BKDM4EPTGDR2
SCHEMBL3858120 0.81 ADAM17 (0.44) ADAM17PLA2G2APPARGCYP2C9KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7576222-B2 N-{[4-(but-2-ynyloxy)phenyl]sulfonyl}-1-(2-fluorobenzyl)-5-methoxy-2-methyltryptophan; for treatment of rheumatoid arthritis, juvenile rheumatoid arthritis, ulcerative colitis, or Crohn's disease WYETH (US) 2009-08-18 US disclosed
US-20060160884-A1 Alkynyl-containing tryptophan derivative inhibitors of tace/matrix metalloproteinase WYETH (US) 2006-07-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060160884-A1 Alkynyl-containing tryptophan derivative inhibitors of tace/matrix metalloproteinase ADAM17, TPSAB1, ADAM10 ADAM17 1/4885PLA2G2A 3197/4885PPARG 4511/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.